Filtered By:
Specialty: Consumer Health News
Condition: Ischemic Stroke
Drug: Tysabri
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Topline Results Negative for MS Drug in Acute Stroke Topline Results Negative for MS Drug in Acute Stroke
After natalizumab showed some initial promise in improving clinical outcomes in acute ischemic stroke in a phase 2a study, a phase 2b trial of the drug finds no clinical benefit.Medscape Medical News
Source: Medscape Medical News Headlines - February 9, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
